|
Dynavax Advances Agonist For Asthma Into The Clinic
Seeking Alpha Dynavax Technologies Corporation (DVAX) announced this morning it will advance its proprietary second-generation TLR-9 agonist for asthma into Phase 1 clinical studies. The work will be performed under the terms of a collaboration with AstraZeneca … Dynavax to Initiate Phase 1 Studies for TLR-9 Agonist for Asthma |
View full post on asthma – Google News